ABSTRACT
Context Real-life data consist of exhaustive and unbiased data to study drug-safety profiles but are underused because of their complex temporality (i.e., safety depends on the dose, timing, and duration of treatment) and the considerable number of potential side effects to study. We aimed to create a pipeline that manages the complex temporality of real-life data using a data-driven strategy (i.e., without any hypothesis on the potential side effects to search for) to highlight the safety profile of a given drug. We used hydroxychloroquine (HCQ) and its co-prescription in a real-life database to illustrate this pipeline.
Methods We incorporated a weighted cumulative exposure statistical model into a data-driven strategy. This pipeline makes it possible to highlight both long-term and short-term side effects, while avoiding false positives due to the natural course of the underlying disease. We applied the proposed pipeline to a cohort of 2,010 patients with a prescription of HCQ and used their drug prescription as the source of data to highlight the HCQ safety profile.
Results The proposed pipeline introduces a bootstrap strategy into weighted cumulative-exposure statistics estimates to highlight significant drug signals. As applied to HCQ, the proposed pipeline showed nine drugs to be significantly associated with HCQ exposure. Of note, one of them has therapeutic indications for known HCQ side effects. Other associations could be explained by therapeutic indications linked to conditions associated with HCQ indications in France.
Conclusion We propose a data-driven pipeline that makes it possible to provide a broad picture of the side effects of a given drug. It would be informative to pursue the development of this pipeline using other sources of data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CER-APHP CENTRE, IRB 20180603
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST All authors declare that they have no competing interests for this work.
FUNDING No funding was received for this work.
Data Availability
Data not available
